NYSE$NUVB
Nuvation Bio Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Nuvation Bio reported financial results for the third quarter ended September 30, 2022, and provided a business update.
Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share, and had cash, cash equivalents and marketable securities of $673.9 million as of September 30, 2022.
- Dosing is underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors.
- Expect to initiate Phase 1b combination study of NUV-868 by the end of 2022.
- The company is on track to nominate first clinical candidate from Drug-Drug Conjugate (DDC) platform by the end of 2022.
- The company's strong financial position provides cash runway through 2028.
Headline financials
Revenue & EPS history
Nuvation Bio · Revenue · Quarterly
$0
Forward guidance
The company provided forward-looking statements regarding the expected timing of clinical trial initiation, the expected timing of clinical candidate nomination from the DDC platform, Nuvation Bio’s cash runway and the potential therapeutic benefit of its product candidates.
Tailwinds
- Statements regarding the expected timing of clinical trial initiation
- Statements regarding the expected timing of clinical candidate nomination from the DDC platform
- Statements regarding Nuvation Bio’s cash runway
- Statements regarding the potential therapeutic benefit of its product candidates
Headwinds
- Challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products
- The emergence or worsening of adverse events or other undesirable side effects
- Risks associated with preliminary and interim data, which may not be representative of more mature data
- Risks related to cost reduction efforts
- Competitive developments
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.1%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+9.3%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+16.4%
Q3 2023
Best reaction
-25.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +6.7% | +4.9% | |
| Q4 2025 | -25.2% | -21.4% | -24.5% | |
| Q3 2025 | -6.2% | -8.5% | +60.7% | |
| Q1 2025 | +3.5% | +7.4% | +21.6% | |
| Q4 2024 | +1.0% | +0.0% | +0.5% | |
| Q3 2024 | +12.9% | +29.7% | +22.8% | |
| Q2 2024 | -11.3% | -15.8% | -10.4% | |
| Q1 2024 | -2.1% | -1.5% | -11.3% | |
| Q4 2023 | +13.2% | +10.7% | +84.8% | |
| Q3 2023 | +16.4% | +15.5% | +14.7% | |
| Q2 2023 | +0.5% | +12.0% | -10.4% | |
| Q1 2023 | +4.4% | +0.6% | +6.9% | |
| Q4 2022 | +1.2% | +0.6% | +8.4% | |
| Q3 2022 | -3.7% | -7.4% | -7.8% | |
| Q2 2022 | +7.8% | +12.1% | +26.8% | |
| Q1 2022 | -1.8% | -9.3% | -18.4% | |
| Q4 2021 | -8.3% | -13.7% | +0.8% | |
| Q3 2021 | +3.6% | +6.2% | +4.0% | |
| Q2 2021 | +8.6% | +4.3% | +11.1% | |
| Q1 2021 | +8.9% | +26.7% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro